ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 195

Activation of the Pyrin Inflammasome through the RhoA Signaling Pathway in Familial Mediterranean Fever (FMF) and Hyperimmunoglobulinemia D Syndrome (HIDS)

Yong Hwan Park, Geryl Wood, Daniel Kastner and Jae Jin Chae, Metabolic, Cardiovascular, and Inflammatory Disease Genomics Branch, NIH/NHGRI, Bethesda, MD

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Familial Mediterranean fever, IL-1, inflammasome activation, inflammation and pathogenesis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Innate Immunity and Rheumatic Disease Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Mutations in the genes encoding pyrin and mevalonate kinase (MVK) cause the autoinflammatory diseases familial Mediterranean fever (FMF) and hyperimmunoglobulinemia D syndrome (HIDS), respectively.  The inflammation of both diseases is mediated by interleukin-1β (IL-1β).  Recently it has been reported that pyrin forms an inflammasome, a multiprotein complex that mediates the maturation of IL-1β by activating caspase-1, in response to bacterial modifications of RhoA.  However, the precise molecular mechanism of pyrin inflammasome activation, as well as the mechanism by which FMF-associated mutations activate pyrin, remain to be elucidated.  Thus, here we investigated the molecular mechanism of pyrin inflammasome activation and the molecular pathogenesis of FMF and HIDS.

Methods: We studied IL-1β production in immune cells from wild type mice and from several knockout and knockin mouse strains, as well as from FMF and HIDS patients and healthy controls, in response to LPS and/or various other bacterial toxins, and in the presence of pharmacologic agents targeting the Rho GTPase or adenylate cyclase pathways.  Protein interactions were studied by immunoprecipitation.

Results: The Clostridial TcdB and C3 toxins, which inactivate RhoA, activate IL-1β maturation by a pathway that is Mefv-, Asc-, and Caspase-1-dependent, but Nlrp3-, Nlrc4-, and Aim2-independent.  IL-1β secretion induced by the Clostridial toxins or from bone marrow-derived macrophages (BMDMs) of FMF knockin (KI) mice is inhibited both by the bacterial CNF toxin, which activates RhoA, and by colchicine.  Colchicine also inhibits the constitutive IL-1β secretion from peripheral blood mononuclear cells (PBMCs) of FMF patients.  In addition, the constitutive IL-1b secretion from FMF patients’ PBMCs or BMDMs of FMF-KI mice is potentiated by cAMP, which has a role in suppressing RhoA through PKA-mediated direct phosphorylation.  RhoA inhibition-induced inflammasome activation is mediated by reduced activities of downstream RhoA-effector kinase, serine/threonine protein kinase C-related kinase (PKN/PRK).  The kinase domain of PKN binds to pyrin directly and phosphorylates two serine residues (S208 and S242 of human pyrin).  The phosphorylated pyrin is recognized by 14-3-3 proteins, which negatively regulate the pyrin inflammasome.  The binding affinity of 14-3-3 proteins as well as PKN for FMF-associated mutant pyrin is substantially lower than for wild-type pyrin, and the constitutive IL-1β secretion from FMF or HIDS patients’ PBMCs or macrophages of FMF-KI mice is attenuated by activating PKNs. Defects in prenylation, seen in HIDS, lead to RhoA inactivation and consequent pyrin inflammasome activation. Taken together, these data suggest that the inflammations in FMF or HIDS are caused by the constitutive activation of the pyrin inflammasome due to the decreased interaction of pyrin with 14-3-3 proteins.

Conclusion: These data directly implicate Rho GTPase in the regulation of the pyrin inflammasome, and suggest that this pathway is also important in HIDS.


Disclosure: Y. H. Park, None; G. Wood, None; D. Kastner, None; J. J. Chae, None.

To cite this abstract in AMA style:

Park YH, Wood G, Kastner D, Chae JJ. Activation of the Pyrin Inflammasome through the RhoA Signaling Pathway in Familial Mediterranean Fever (FMF) and Hyperimmunoglobulinemia D Syndrome (HIDS) [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/activation-of-the-pyrin-inflammasome-through-the-rhoa-signaling-pathway-in-familial-mediterranean-fever-fmf-and-hyperimmunoglobulinemia-d-syndrome-hids/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/activation-of-the-pyrin-inflammasome-through-the-rhoa-signaling-pathway-in-familial-mediterranean-fever-fmf-and-hyperimmunoglobulinemia-d-syndrome-hids/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology